Bronchoscopy in Patients With Known or Suspected COVID-19: Results From the Global Pandemic SARS-CoV-2 Bronchoscopy Database (GPS-BD)
| Autor: | Gustavo Cumbo-Nacheli, Elaine Yap, Henri G. Colt, Robert J. Lentz, Joseph Cicenia, Jonathan P. Williamson, Francesco Tarantini, Lorenzo Corbetta, Ameena Goga, Patricia Vujacich, Hans J. Lee, Septimiu D. Murgu, Jasleen Pannu, Michal Senitko, Akhil D. Goel, Abhinav Agrawal |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Coronavirus disease 2019 (COVID-19) medicine.diagnostic_test Database business.industry SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Pulmonary Surgical Procedures COVID-19 medicine.disease computer.software_genre Comorbidity Bronchoscopy Pandemic medicine Humans In patient Adverse effect business computer Pandemics bronchoscopy global health practices pulmonary surgical procedures Severe Acute Respiratory Syndrome Coronavirus 2 Retrospective Studies |
| Zdroj: | Journal of bronchologyinterventional pulmonology. 29(2) |
| ISSN: | 1948-8270 |
| Popis: | Background: Amid the Coronavirus Disease 2019 (COVID-19) pandemic, the benefits and risks of bronchoscopy remain uncertain. This study was designed to characterize bronchoscopy-related practice patterns, diagnostic yields, and adverse events involving patients with known or suspected COVID-19. Methods: An online survey tool retrospectively queried bronchoscopists about their experiences with patients with known or suspected COVID-19 between March 20 and August 20, 2020. Collected data comprised the Global Pandemic SARS-CoV-2 Bronchoscopy Database (GPS-BD). All bronchoscopists and patients were anonymous with no direct investigator-to-respondent contact. Results: Bronchoscopy procedures involving 289 patients from 26 countries were analyzed. One-half of patients had known COVID-19. Most (82%) had at least 1 pre-existing comorbidity, 80% had at least 1 organ failure, 51% were critically ill, and 37% were intubated at the time of the procedure. Bronchoscopy was performed with diagnostic intent in 166 (57%) patients, yielding a diagnosis in 86 (52%). and management changes in 80 (48%). Bronchoscopy was performed with therapeutic intent in 71 (25%) patients, mostly for secretion clearance (87%). Complications attributed to bronchoscopy or significant clinical decline within 12 hours of the procedure occurred in 24 (8%) cases, with 1 death. Conclusion: Results from this international database provide a widely generalizable characterization of the benefits and risks of bronchoscopy in patients with known or suspected COVID-19. Bronchoscopy in this setting has reasonable clinical benefit, with diagnosis and/or management change resulting from about half of the diagnostic cases. However, it is not without risk, especially in patients with limited physiological reserve. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|